MXPA03011083A - Compuestos de sulfonamida sustituida, procedimiento para su preparacion, y su uso como medicamento para el tratamiento de trastornos del sistema nervioso central. obesidad y diabetes tipo ii. - Google Patents
Compuestos de sulfonamida sustituida, procedimiento para su preparacion, y su uso como medicamento para el tratamiento de trastornos del sistema nervioso central. obesidad y diabetes tipo ii.Info
- Publication number
- MXPA03011083A MXPA03011083A MXPA03011083A MXPA03011083A MXPA03011083A MX PA03011083 A MXPA03011083 A MX PA03011083A MX PA03011083 A MXPA03011083 A MX PA03011083A MX PA03011083 A MXPA03011083 A MX PA03011083A MX PA03011083 A MXPA03011083 A MX PA03011083A
- Authority
- MX
- Mexico
- Prior art keywords
- obesity
- diabetes
- treatment
- type
- medicament
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
La presente invencion se refiere a compuestos de sulfonamida sustituida de la formula general (I), en la cual P es acido sulfonico sustituido con sulfonamida o sustituido con amida, cuyos compuestos son potencialmente utiles para la profilaxis y tratamiento de condiciones medicas relacionadas con obesidad, diabetes tipo II y/o trastornos del sistema nervioso central.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0102048A SE0102048D0 (sv) | 2001-06-11 | 2001-06-11 | New Compounds |
SE0102386A SE0102386D0 (sv) | 2001-07-03 | 2001-07-03 | New compounds |
SE0103437A SE0103437D0 (sv) | 2001-10-16 | 2001-10-16 | New compounds |
PCT/SE2002/001126 WO2002100822A1 (en) | 2001-06-11 | 2002-06-11 | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03011083A true MXPA03011083A (es) | 2004-07-08 |
Family
ID=27354709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03011083A MXPA03011083A (es) | 2001-06-11 | 2002-06-11 | Compuestos de sulfonamida sustituida, procedimiento para su preparacion, y su uso como medicamento para el tratamiento de trastornos del sistema nervioso central. obesidad y diabetes tipo ii. |
Country Status (17)
Country | Link |
---|---|
US (5) | US7144883B2 (es) |
EP (1) | EP1412325A1 (es) |
JP (2) | JP4731114B2 (es) |
KR (3) | KR100888906B1 (es) |
CN (2) | CN100457726C (es) |
AU (1) | AU2002309435B2 (es) |
BR (1) | BR0210291A (es) |
CA (1) | CA2445653A1 (es) |
EA (1) | EA008476B1 (es) |
HK (1) | HK1066790A1 (es) |
IL (1) | IL158590A0 (es) |
MX (1) | MXPA03011083A (es) |
NO (1) | NO20035496D0 (es) |
NZ (1) | NZ529032A (es) |
PL (1) | PL367264A1 (es) |
WO (1) | WO2002100822A1 (es) |
YU (1) | YU98003A (es) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7517884B2 (en) | 1998-03-30 | 2009-04-14 | Kalypsys Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
MXPA03011083A (es) | 2001-06-11 | 2004-07-08 | Biovitrum Ab | Compuestos de sulfonamida sustituida, procedimiento para su preparacion, y su uso como medicamento para el tratamiento de trastornos del sistema nervioso central. obesidad y diabetes tipo ii. |
AU2003213185A1 (en) * | 2002-02-22 | 2003-09-09 | Pharmacia And Upjohn Company | Arylsulfone derivatives |
GB0204720D0 (en) * | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Novel use |
NZ552283A (en) * | 2002-06-20 | 2008-07-31 | Biovitrum Ab Publ | New compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
US7943639B2 (en) | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
EP1897876A3 (en) * | 2002-06-20 | 2009-03-18 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
NZ538713A (en) | 2002-08-12 | 2007-01-26 | Takeda Chemical Industries Ltd | Fused benzene derivative and use |
SE0301446D0 (sv) * | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
ES2228267B1 (es) * | 2003-07-30 | 2006-07-01 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6. |
ES2228268B1 (es) * | 2003-07-30 | 2006-07-01 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6. |
GB0320320D0 (en) * | 2003-08-29 | 2003-10-01 | Glaxo Group Ltd | Novel compounds |
GB0321473D0 (en) | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
SE0302760D0 (sv) * | 2003-10-20 | 2003-10-20 | Biovitrum Ab | New compounds |
AU2004299438A1 (en) * | 2003-12-19 | 2005-06-30 | Biovitrum Ab | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-HT6 receptor-related disorder |
SE0303480D0 (sv) | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
GB0407025D0 (en) * | 2004-03-29 | 2004-04-28 | Glaxo Group Ltd | Novel compounds |
JP2008502652A (ja) * | 2004-06-18 | 2008-01-31 | ノイロサーチ アクティーゼルスカブ | モノアミン神経伝達物質再取込み阻害剤としての、新規アルキル置換ピペラジン誘導体及びその使用 |
WO2006047302A1 (en) * | 2004-10-21 | 2006-05-04 | Transtech Pharma, Inc. | Bissulfonamide compounds as agonists of galr1, compositions, and methods of use |
BRPI0516435B1 (pt) | 2004-10-29 | 2021-09-21 | Kalypsys , Inc | Composto, e composição farmacêutica |
WO2006062481A1 (en) * | 2004-12-09 | 2006-06-15 | Biovitrum Ab | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
EP1676842A1 (en) * | 2004-12-30 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments |
US7582767B2 (en) * | 2005-06-17 | 2009-09-01 | Biovitrum Ab (Publ.) | Substituted sulphonamide compound and uses thereof |
US7863276B2 (en) | 2005-10-25 | 2011-01-04 | Kalypsys, Inc | Salts of modulators of PPAR and methods of treating metabolic disorders |
UY30048A1 (es) | 2005-12-23 | 2007-07-31 | Astrazeneca Ab | Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones |
CN101404987A (zh) * | 2006-01-20 | 2009-04-08 | 史密丝克莱恩比彻姆公司 | 磺酰胺衍生物在治疗代射和神经系统疾病中的用途 |
WO2007108743A2 (en) * | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators ii |
WO2007108744A2 (en) * | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators |
EP1999121A1 (en) * | 2006-03-17 | 2008-12-10 | AstraZeneca AB | Novel tetralins as 5-ht6 modulators |
EP1837332A1 (en) * | 2006-03-23 | 2007-09-26 | Laboratorios Del Dr. Esteve, S.A. | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments |
TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
WO2008091863A1 (en) | 2007-01-23 | 2008-07-31 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
EP2139481B1 (en) | 2007-03-21 | 2013-08-21 | The University Of Montana | 1-[(2'-substituted)-piperazin-1'-yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents |
DE602007012683D1 (de) * | 2007-07-19 | 2011-04-07 | Esteve Labor Dr | Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente |
CN101417987B (zh) * | 2007-10-24 | 2011-07-13 | 山东轩竹医药科技有限公司 | 具有磺酰胺甲酰哌嗪结构的dpp-iv抑制剂 |
JP2011512340A (ja) * | 2008-02-15 | 2011-04-21 | エフ.ホフマン−ラ ロシュ アーゲー | 3−アルキルピペラジン誘導体及びその使用 |
DE102008019838A1 (de) * | 2008-04-19 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
WO2010102286A2 (en) * | 2009-03-06 | 2010-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Proteasome inhibitors having chymotrypsin-like activity |
MX346801B (es) | 2009-03-13 | 2017-03-31 | Agios Pharmaceuticals Inc | Métodos y composiciones para trastornos relacionados con la proliferación celular. |
JP5756457B2 (ja) | 2009-04-06 | 2015-07-29 | アジオス ファーマシューティカルズ, インコーポレイテッド | ピルビン酸キナーゼm2調節剤、治療組成物および関連する使用方法 |
UA107080C2 (uk) * | 2009-04-30 | 2014-11-25 | Сполуки n-феніл(піперазиніл або гомопіперазиніл)бензолсульфонаміду або бензолсульфонілфеніл(піперазину або гомопіперазину), придатні для лікування захворювань, які реагують на модулювання рецептора 5-ht6 серотоніну | |
MX2012000256A (es) | 2009-06-29 | 2012-04-19 | Agios Pharmaceuticals Inc | Compuestos terapeuticos y composiciones. |
EP3064595B1 (en) | 2009-10-21 | 2019-02-27 | Agios Pharmaceuticals, Inc. | Methods for cell-proliferation-related disorders |
US9394294B2 (en) | 2010-05-11 | 2016-07-19 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
US8765737B1 (en) | 2010-05-11 | 2014-07-01 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
US8802832B2 (en) | 2010-06-22 | 2014-08-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
US9586954B2 (en) | 2010-06-22 | 2017-03-07 | Demerx, Inc. | N-substituted noribogaine prodrugs |
US8741891B1 (en) | 2010-06-22 | 2014-06-03 | Demerx, Inc. | N-substituted noribogaine prodrugs |
US9358237B2 (en) | 2010-07-23 | 2016-06-07 | Demerx, Inc. | Noribogaine compositions |
WO2012083246A1 (en) | 2010-12-17 | 2012-06-21 | Agios Pharmaceuticals, Inc. | Novel n- (4- (azetidine - 1 - carbonyl) phenyl) - (hetero - ) arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators |
ES2569712T3 (es) | 2010-12-21 | 2016-05-12 | Agios Pharmaceuticals, Inc. | Activadores de PKM2 bicíclicos |
TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
EP2481740B1 (en) | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
ES2675903T3 (es) | 2011-05-03 | 2018-07-13 | Agios Pharmaceuticals, Inc. | Activadores de piruvato quinasa para uso en terapia |
ES2746558T3 (es) | 2011-05-03 | 2020-03-06 | Agios Pharmaceuticals Inc | Activadores de piruvato cinasa R para uso en terapia |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
US9617274B1 (en) | 2011-08-26 | 2017-04-11 | Demerx, Inc. | Synthetic noribogaine |
WO2013085922A1 (en) | 2011-12-09 | 2013-06-13 | Demerx, Inc. | Phosphate esters of noribogaine |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
CA2858820C (en) | 2012-01-25 | 2021-08-17 | Demerx, Inc. | Synthetic voacangine |
US8940728B2 (en) | 2012-12-20 | 2015-01-27 | Demerx, Inc. | Substituted noribogaine |
US9045481B2 (en) | 2012-12-20 | 2015-06-02 | Demerx, Inc. | Substituted noribogaine |
EP2934541A4 (en) * | 2012-12-20 | 2016-08-03 | Demerx Inc | NORIBOGAINE SUBSTITUTE |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
JP6529492B2 (ja) | 2013-07-11 | 2019-06-12 | アジオス ファーマシューティカルズ, インコーポレイテッド | 癌の処置のためのidh2突然変異体阻害剤としての2,4−または4,6−ジアミノピリミジン化合物 |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
JP6454346B2 (ja) | 2013-12-20 | 2019-01-16 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 芳香族複素環式化合物及び医薬におけるその応用 |
CA2942072C (en) | 2014-03-14 | 2022-07-26 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
WO2015158313A1 (en) | 2014-04-19 | 2015-10-22 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
EP2998294A1 (en) * | 2014-09-16 | 2016-03-23 | Sanofi | Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
EP2997966A1 (en) * | 2014-09-16 | 2016-03-23 | Sanofi | Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders |
EP2998295A1 (en) * | 2014-09-16 | 2016-03-23 | Sanofi | Aryl substituted naphthyl sulfonamide derivatives as keap-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
US11234976B2 (en) | 2015-06-11 | 2022-02-01 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
UA123400C2 (uk) | 2015-10-15 | 2021-03-31 | Аджиос Фармасьютікалз, Інк. | Комбінована терапія для лікування злоякісних пухлин |
KR20180061372A (ko) | 2015-10-15 | 2018-06-07 | 아지오스 파마슈티컬스 아이엔씨. | 악성 종양의 치료를 위한 조합물 요법 |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB947606A (en) | 1961-04-10 | 1964-01-22 | Ici Ltd | N-substituted piperazines |
EP0126087A1 (en) | 1982-09-24 | 1984-11-28 | Beecham Group Plc | Amino-azabicycloalkyl derivatives as dopamine antagonists |
US4808595A (en) * | 1986-12-24 | 1989-02-28 | Merck & Co., Inc. | Furopyridine sulfonamides and their opthalmological compositions |
JP2810236B2 (ja) | 1993-03-16 | 1998-10-15 | フアイザー・インコーポレイテツド | ナフタレン誘導体 |
US5597826A (en) * | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
US5939451A (en) | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
TR200000073T2 (tr) | 1997-07-11 | 2000-06-21 | Smithkline Beecham P.L.C. | 5-HT6 Reseptör antagonistleri olan sülfonamid türevleri ve bunların hazırlanma prosesi |
ATE404539T1 (de) * | 1997-10-02 | 2008-08-15 | Eisai R&D Man Co Ltd | Kondensierte pyridinderivate |
JP3989102B2 (ja) * | 1997-10-02 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 縮合ピリジン誘導体 |
GB9801392D0 (en) | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
GB9803411D0 (en) | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
GB9818916D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
WO2000034242A1 (en) | 1998-12-11 | 2000-06-15 | Virginia Commonwealth University | Selective 5-ht6 receptor ligands |
GB9904995D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Substituted aza-oxindole derivatives |
DE19934321A1 (de) * | 1999-07-21 | 2001-01-25 | Bayer Ag | Naphthyl-substituierte Sulfonamide |
WO2001032660A1 (en) | 1999-11-05 | 2001-05-10 | Nps Allelix Corp. | Compounds having 5-ht6 receptor antagonist activity |
GB9926302D0 (en) | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
WO2001085722A1 (en) | 2000-05-05 | 2001-11-15 | Cor Therapeutics, Inc. | Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors |
JP2004503553A (ja) | 2000-06-14 | 2004-02-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 6,5−縮合二環式複素環 |
BR0114552A (pt) | 2000-10-20 | 2003-07-01 | Biovitrum Ab | N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia |
NZ528450A (en) | 2001-05-11 | 2006-02-24 | Biovitrum Ab | Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders |
KR100600240B1 (ko) | 2001-06-07 | 2006-07-13 | 에프. 호프만-라 로슈 아게 | 5-ht6 수용체 친화도를 갖는 신규한 인돌 유도체 |
MXPA03011083A (es) | 2001-06-11 | 2004-07-08 | Biovitrum Ab | Compuestos de sulfonamida sustituida, procedimiento para su preparacion, y su uso como medicamento para el tratamiento de trastornos del sistema nervioso central. obesidad y diabetes tipo ii. |
US7943639B2 (en) * | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
-
2002
- 2002-06-11 MX MXPA03011083A patent/MXPA03011083A/es active IP Right Grant
- 2002-06-11 IL IL15859002A patent/IL158590A0/xx unknown
- 2002-06-11 BR BR0210291-9A patent/BR0210291A/pt not_active IP Right Cessation
- 2002-06-11 YU YU98003A patent/YU98003A/sh unknown
- 2002-06-11 CA CA002445653A patent/CA2445653A1/en not_active Abandoned
- 2002-06-11 NZ NZ529032A patent/NZ529032A/en unknown
- 2002-06-11 CN CNB028103777A patent/CN100457726C/zh not_active Expired - Fee Related
- 2002-06-11 JP JP2003503591A patent/JP4731114B2/ja not_active Expired - Fee Related
- 2002-06-11 KR KR1020087016920A patent/KR100888906B1/ko not_active IP Right Cessation
- 2002-06-11 PL PL02367264A patent/PL367264A1/xx not_active Application Discontinuation
- 2002-06-11 US US10/167,141 patent/US7144883B2/en not_active Expired - Fee Related
- 2002-06-11 KR KR1020037016203A patent/KR100889718B1/ko not_active IP Right Cessation
- 2002-06-11 AU AU2002309435A patent/AU2002309435B2/en not_active Ceased
- 2002-06-11 EA EA200400027A patent/EA008476B1/ru not_active IP Right Cessation
- 2002-06-11 WO PCT/SE2002/001126 patent/WO2002100822A1/en active Application Filing
- 2002-06-11 CN CNA2005101381444A patent/CN1800185A/zh active Pending
- 2002-06-11 EP EP02778916A patent/EP1412325A1/en not_active Withdrawn
- 2002-06-11 KR KR1020097000129A patent/KR20090019894A/ko not_active Application Discontinuation
-
2003
- 2003-12-10 NO NO20035496A patent/NO20035496D0/no not_active Application Discontinuation
-
2004
- 2004-12-14 HK HK04109896.2A patent/HK1066790A1/xx not_active IP Right Cessation
-
2006
- 2006-08-25 US US11/509,914 patent/US20070066598A1/en not_active Abandoned
- 2006-08-25 US US11/509,989 patent/US20070066599A1/en not_active Abandoned
- 2006-08-25 US US11/510,324 patent/US7572787B2/en not_active Expired - Fee Related
-
2009
- 2009-09-10 JP JP2009209444A patent/JP2010013473A/ja not_active Withdrawn
-
2010
- 2010-05-17 US US12/781,355 patent/US20100222330A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100222330A1 (en) | 2010-09-02 |
US20070066600A1 (en) | 2007-03-22 |
EP1412325A1 (en) | 2004-04-28 |
JP2004536080A (ja) | 2004-12-02 |
NZ529032A (en) | 2007-04-27 |
IL158590A0 (en) | 2004-05-12 |
JP2010013473A (ja) | 2010-01-21 |
CN100457726C (zh) | 2009-02-04 |
KR100888906B1 (ko) | 2009-03-16 |
PL367264A1 (en) | 2005-02-21 |
KR20040007688A (ko) | 2004-01-24 |
KR100889718B1 (ko) | 2009-03-23 |
US20070066599A1 (en) | 2007-03-22 |
CN1800185A (zh) | 2006-07-12 |
AU2002309435B2 (en) | 2008-08-14 |
WO2002100822A1 (en) | 2002-12-19 |
HK1066790A1 (en) | 2005-04-01 |
CN1522245A (zh) | 2004-08-18 |
BR0210291A (pt) | 2004-07-13 |
KR20090019894A (ko) | 2009-02-25 |
NO20035496D0 (no) | 2003-12-10 |
US20030158202A1 (en) | 2003-08-21 |
US7572787B2 (en) | 2009-08-11 |
US7144883B2 (en) | 2006-12-05 |
EA008476B1 (ru) | 2007-06-29 |
US20070066598A1 (en) | 2007-03-22 |
EA200400027A1 (ru) | 2004-04-29 |
YU98003A (sh) | 2006-03-03 |
JP4731114B2 (ja) | 2011-07-20 |
CA2445653A1 (en) | 2002-12-19 |
KR20080080172A (ko) | 2008-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03011083A (es) | Compuestos de sulfonamida sustituida, procedimiento para su preparacion, y su uso como medicamento para el tratamiento de trastornos del sistema nervioso central. obesidad y diabetes tipo ii. | |
MXPA03010232A (es) | Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central. | |
MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
ATE365720T1 (de) | Agonisten von beta-adrenorezeptoren | |
AP2088A (en) | Phenethanolamine derivatives for treatment of respiratory diseases | |
MXPA04002405A (es) | Derivados de fenetanolamina para tratamiento de enfermedades respiratorias. | |
MXPA05013366A (es) | Derivados de benzazepina utiles para el tratamiento de enfermedades asociadas con el receptor 5ht2c. | |
EA200500054A1 (ru) | Новые соединения, применимые для лечения ожирения, сахарного диабета ii типа и расстройств центральной нервной системы | |
PL370381A1 (en) | Substituted piperazines as modulators of the melanocortin receptor | |
BR0310106A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica | |
NO20055649L (no) | Substituert dihydrokinazolin med antiviale egenskaper | |
SE0403006D0 (sv) | New compounds | |
EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
BRPI0508927A (pt) | compostos úteis para o tratamento de doenças | |
MXPA03008635A (es) | Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades. | |
WO2003070728A3 (en) | Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders | |
IL161047A0 (en) | Pyrazole derivatives for increasing endogenous testosterone levels | |
TW200728281A (en) | Novel N-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions | |
SE0101082D0 (sv) | Novel use | |
TW200510354A (en) | Benzoxazinone-derived sulphonamide compounds, their preparation and use as medicaments | |
SE0102048D0 (sv) | New Compounds | |
RS88803A (en) | Novel-arylsulfonamide compounds for the treatment of obesity type ii diabetes and cns-disorders | |
WO2003004460A3 (en) | Succinic acid derivatives | |
DOP2002000472A (es) | Amidas de acido piperazinciclohexanocarboxilico sustituidas y su utilizacion. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |